For further information please contact: Verona P Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique ...

The company bagged FDA approval for first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor Ohtuvayre (ensifentrine) last June, becoming the first inhaled product with a novel mechanism of ...

shortly after Verona Pharma got the go-ahead from the US FDA for its PDE 3/4 inhibitor Ohtuvayre (ensifentrine). Dupixent – which is due for a verdict from the FDA as a COPD therapy later this ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD). Design ...

Two reviewers (IPK and KGM) independently searched the aforementioned databases to identify potentially eligible trials. To be included in our analysis, a trial had to be an RCT, and to focus on ...

Sanofi S.A. Part Cert-1.97% €8.03M ...

Barbara Obstoj-Cardwell is the Managing Editor of The Pharma Letter, which in 2010 acquired the archives of The Pharma Marketletter, a publication that Barbara owned since 1991 and prior to that ...